Skip to main content
SpringerLink
Log in
Book cover

Liposuction pp 109–118Cite as

Drugs to Limit Use of or Avoid When Performing Liposuction

  • Chapter
  • First Online:

  • 1742 Accesses

Abstract

A surgeon should be aware of what drugs the patient should avoid before any surgery is performed. This is most important with nonemergency procedures such as liposuction. Estrogens are a significant risk factor in thromboembolism, while cytochrome P450 3A4 inhibitors can prevent the breakdown of lidocaine and result in lidocaine toxicity. The author discusses the use of herbals by patients and Toradol by surgeons.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Physician Desk Reference is Editor, Montvale: Medical Economics Company. Physicians’ Desk Reference. 52nd ed. 1998. p. 3070.

    Google Scholar 

  2. Shiffman MA. Guidelines for the prevention of venous thromboembolism. Am J Cosmet Surg. 2000;17(2):103–4.

    Google Scholar 

  3. Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. Br Med J. 1986;292(6519):526.

    Article  CAS  Google Scholar 

  4. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1995;346(8990):1575–82.

    Google Scholar 

  5. Gerstman B, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol. 1991;133(1):32–7.

    CAS  PubMed  Google Scholar 

  6. Carr B, Ory H. Estrogen and progestin components of oral contraceptives relationship to vascular disease. Contraception. 1997;55(5):267–72.

    Article  CAS  PubMed  Google Scholar 

  7. Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy. A report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center. N Engl J Med. 1974;290(1):15–9.

    Google Scholar 

  8. Petitti DB, Wingerd J, Pellegrin F, Ramcharan S. Risk of vascular disease in women. Smoking, oral contraceptives, noncontraceptive estrogens, and other factors. J Am Med Assoc. 1979;242(110):1150–4.

    Article  CAS  Google Scholar 

  9. Devor M, Barrett-Connor E, Renvall M, Feigal DJ, Ramsdell J. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med. 1992;92(3):275–82.

    Article  CAS  PubMed  Google Scholar 

  10. Nachtigall LE, Nachtigall RH, Nachtigal RD, Beckman EM. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol. 1979;54(1):74–9.

    Article  CAS  PubMed  Google Scholar 

  11. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 1996;348(9033):977–80.

    Article  CAS  PubMed  Google Scholar 

  12. Barrett-Connor DM, Renvall M, Ramsdell J. Estrogen replacement and the risk of venous thrombosis. Am J Med. 1992;92(3):275–82.

    Article  PubMed  Google Scholar 

  13. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet. 1996;348(9033):981–3.

    Article  CAS  PubMed  Google Scholar 

  14. Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 1996;348(9033):983–7.

    Article  CAS  PubMed  Google Scholar 

  15. Perez Gutthann S, Garcia Rodriguez L, Castellsague J, Duque Oliart A. Hormone replacement therapy and the risk of venous thromboembolism: population based case control study. Br Med J. 1997;314(7083):796–800.

    Article  CAS  Google Scholar 

  16. Varas-Lorenzo C, Garcia-Rodriguez L, Cattaruzzi C, Troncon MG, Agostinis L, Perez-Gutthann S. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe. Am J Epidemiol. 1998;147(4):387–90.

    Article  CAS  PubMed  Google Scholar 

  17. Grady D, Hulley SB, Furberg C. Venous thromboembolic events associated with hormone replacement therapy. J Am Med Assoc. 1997;278(6):477.

    Article  CAS  Google Scholar 

  18. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J Am Med Assoc. 1998;280(7):605–13.

    Article  CAS  Google Scholar 

  19. Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, Vittinghoff E, Hulley S. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the Heart and Estrogen/progestin Replacement Study. Ann Int Med. 2000;132(9):689–96.

    Article  CAS  PubMed  Google Scholar 

  20. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. J Am Med Assoc. 1996;279(20):1643–50.

    Article  Google Scholar 

  21. Mullins R. Quoted by Woznicki A. Herbs. Readers Digest, July 2000. p. 49–51.

    Google Scholar 

  22. Fugh-Berman A. Herb-drug interactions. Lancet. 2000;355(9198):134–5.

    Article  CAS  PubMed  Google Scholar 

  23. Windrum P, Hull DR, Morris TC. Herb-drug interactions. Lancet. 2000;355(9208):1019–20.

    Article  CAS  PubMed  Google Scholar 

  24. Herbs and Health. Harv Heart Lett. Heart effects of herbal medicines. 2000;10(7):3–4.

    Google Scholar 

  25. PDR for herbal medications, 1st ed. Montvale: Medical Economics Company; 1998.

    Google Scholar 

  26. Kaye A. Quoted by Davis, R.: Dangers of herbals. USA Today, 30 May 2000. p. 1A.

    Google Scholar 

  27. Cherken L. What you don’t know about herbs and drugs can hurt you. Family Circle, 12 Sept 2000. p. 90.

    Google Scholar 

  28. Baumann TJ. Place of ketorolac in pain management. Clin Pharm. 1990;9(12):938.

    CAS  PubMed  Google Scholar 

  29. Cataldo PA, Senagore AJ, Kilbride MJ. Ketorolac and patient controlled analgesia in the treatment of postoperative pain. Surg Gynecol Obstet. 1993;176(5):435–8.

    CAS  PubMed  Google Scholar 

  30. Freie HM. Treatment of moderate and severe pain. Ketorolac–a new analgesic. Fortschr Med. 1991;109(3):643–6.

    CAS  PubMed  Google Scholar 

  31. O’Donovan S, Ferrara A, Larach S, Williamson P. Intraoperative use of Toradol facilitates outpatient hemorrhoidectomy. Dis Colon Rectum. 1994;37(8):793–9.

    Article  PubMed  Google Scholar 

  32. Richman IM. Use of Toradol in anorectal surgery. Dis Colon Rectum. 1993;36(3):295–6.

    Article  CAS  PubMed  Google Scholar 

  33. Spindler JS, Mehlisch D, Brown CR. Intraoperative ketorolac and morphine in the treatment of moderate to severe pain after major surgery. Pharmacotherapy. 1990;10(6 Pt 2):51–8.

    Google Scholar 

  34. Stanski DR, Cherry C, Bradley R, Sarnquist FH, Yee JP. Efficacy and safety of single doses of intramuscular ketorolac tromethane compared with meperidine for postoperative pain. Pharmacotherapy. 1990;10(Pt 2):40–4.

    Google Scholar 

  35. Gorcha IS, Bostwick J. Postoperative hematomas associated with Toradol. Plast Reconstr Surg. 1991;88(5):919–20.

    Article  Google Scholar 

  36. Conrad KA, Fagan TC, Mackie MJ, Mayshar PV. Effects of ketorolac tromethamine on hemostasis in volunteers. Clin Pharmacol Ther. 1988;43(5):542–6.

    Article  CAS  PubMed  Google Scholar 

  37. Concannon MJ, Welsh CF, Puckett CL. Inhibition of perioperative platelet aggregation using Toradol (ketorolac). South Med J. 1991;84:2S–72.

    Article  Google Scholar 

  38. Pearce CJ, Gonzalez FM, Wallin D. Renal failure and hyperkalemia associated with ketorolac tromethamine. Arch Int Med. 1993;153(8):1000–2.

    Article  CAS  Google Scholar 

  39. Physicians’ Desk Reference. 51st ed. Montvale: Medical Economics Company; 1997. p. 115.

    Google Scholar 

  40. Physicians’ Desk Reference. 52nd ed. Montvale: Medical Economics Company; 1998. p. 113.

    Google Scholar 

  41. Physicians’ Desk Reference. 52nd ed. Montvale: Medical Economics Company; 2000. p. 111.

    Google Scholar 

  42. Physicians’ Desk Reference. 51st ed. Montvale: Medical Economics Company; 1997. p. 462–63.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Private Practice, 17501 Chatham Drive, Tustin, CA, 92780, USA

    Melvin A. Shiffman M.D., J.D.

Authors
  1. Melvin A. Shiffman M.D., J.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Melvin A. Shiffman M.D., J.D. .

Editor information

Editors and Affiliations

  1. Tustin, California, USA

    Melvin A. Shiffman

  2. Department of Plastic Surgery, Regional Hospital-Ancona, Ancona, Italy

    Alberto Di Giuseppe

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Shiffman, M.A. (2016). Drugs to Limit Use of or Avoid When Performing Liposuction. In: Shiffman, M., Di Giuseppe, A. (eds) Liposuction. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-48903-1_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-48903-1_9

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-48901-7

  • Online ISBN: 978-3-662-48903-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation